LeMaitre Vascular, Inc. (NASDAQ:LMAT) – Investment analysts at First Analysis increased their Q1 2018 earnings per share (EPS) estimates for shares of LeMaitre Vascular in a report issued on Tuesday. First Analysis analyst now expects that the medical instruments supplier will post earnings per share of $0.20 for the quarter, up from their previous forecast of $0.19. First Analysis has a “Equal Weight” rating and a $34.00 price objective on the stock. First Analysis also issued estimates for LeMaitre Vascular’s Q2 2018 earnings at $0.22 EPS, Q3 2018 earnings at $0.21 EPS and FY2018 earnings at $0.88 EPS.

LeMaitre Vascular (NASDAQ:LMAT) last announced its quarterly earnings results on Thursday, October 26th. The medical instruments supplier reported $0.25 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.20 by $0.05. The business had revenue of $24.80 million during the quarter, compared to the consensus estimate of $25.49 million. LeMaitre Vascular had a net margin of 15.81% and a return on equity of 16.16%. The business’s revenue was up 6.9% compared to the same quarter last year. During the same quarter last year, the firm earned $0.17 EPS.

COPYRIGHT VIOLATION NOTICE: This story was reported by Watch List News and is owned by of Watch List News. If you are accessing this story on another domain, it was illegally stolen and republished in violation of international trademark & copyright legislation. The original version of this story can be viewed at https://www.watchlistnews.com/q1-2018-eps-estimates-for-lemaitre-vascular-inc-increased-by-analyst-lmat/1678044.html.

A number of other analysts also recently issued reports on LMAT. Benchmark Co. downgraded shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Monday, July 10th. They noted that the move was a valuation call. Canaccord Genuity downgraded shares of LeMaitre Vascular from a “buy” rating to a “hold” rating and set a $28.00 price target for the company. in a report on Monday, July 10th. BidaskClub downgraded shares of LeMaitre Vascular from a “strong-buy” rating to a “buy” rating in a report on Tuesday, July 25th. Stifel Nicolaus restated a “buy” rating and set a $32.00 price target (up previously from $29.00) on shares of LeMaitre Vascular in a report on Sunday, July 30th. Finally, Zacks Investment Research upgraded shares of LeMaitre Vascular from a “hold” rating to a “buy” rating and set a $38.00 price target for the company in a report on Tuesday, August 1st. Seven equities research analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average target price of $32.20.

Shares of LeMaitre Vascular (NASDAQ LMAT) opened at $32.01 on Thursday. The firm has a market capitalization of $608.92 million, a PE ratio of 41.57, a P/E/G ratio of 2.54 and a beta of 0.55.

A number of institutional investors have recently bought and sold shares of the stock. Dimensional Fund Advisors LP increased its holdings in LeMaitre Vascular by 4.4% in the 2nd quarter. Dimensional Fund Advisors LP now owns 968,232 shares of the medical instruments supplier’s stock valued at $30,228,000 after purchasing an additional 40,767 shares during the last quarter. Conestoga Capital Advisors LLC increased its holdings in LeMaitre Vascular by 51.2% in the 3rd quarter. Conestoga Capital Advisors LLC now owns 854,644 shares of the medical instruments supplier’s stock valued at $31,981,000 after purchasing an additional 289,575 shares during the last quarter. Vanguard Group Inc. increased its holdings in LeMaitre Vascular by 23.5% in the 2nd quarter. Vanguard Group Inc. now owns 815,580 shares of the medical instruments supplier’s stock valued at $25,462,000 after purchasing an additional 155,249 shares during the last quarter. State Street Corp increased its holdings in LeMaitre Vascular by 25.2% in the 2nd quarter. State Street Corp now owns 382,824 shares of the medical instruments supplier’s stock valued at $11,951,000 after purchasing an additional 77,009 shares during the last quarter. Finally, Thomson Horstmann & Bryant Inc. increased its holdings in LeMaitre Vascular by 1.8% in the 2nd quarter. Thomson Horstmann & Bryant Inc. now owns 365,977 shares of the medical instruments supplier’s stock valued at $11,425,000 after purchasing an additional 6,638 shares during the last quarter. Hedge funds and other institutional investors own 68.29% of the company’s stock.

In related news, CEO George W. Lemaitre sold 10,000 shares of LeMaitre Vascular stock in a transaction that occurred on Monday, August 7th. The shares were sold at an average price of $33.62, for a total value of $336,200.00. Following the completion of the sale, the chief executive officer now owns 3,436,808 shares in the company, valued at approximately $115,545,484.96. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider David B. Roberts sold 26,683 shares of LeMaitre Vascular stock in a transaction that occurred on Wednesday, August 30th. The shares were sold at an average price of $36.67, for a total transaction of $978,465.61. Following the completion of the sale, the insider now owns 48,108 shares of the company’s stock, valued at approximately $1,764,120.36. The disclosure for this sale can be found here. Insiders sold a total of 237,537 shares of company stock valued at $8,251,182 in the last quarter. 23.70% of the stock is owned by insiders.

LeMaitre Vascular announced that its board has authorized a stock buyback plan on Thursday, July 27th that authorizes the company to repurchase $7.50 million in shares. This repurchase authorization authorizes the medical instruments supplier to buy up to 1.4% of its stock through open market purchases. Stock repurchase plans are often a sign that the company’s board believes its shares are undervalued.

The business also recently announced a quarterly dividend, which will be paid on Thursday, December 7th. Investors of record on Wednesday, November 22nd will be issued a $0.055 dividend. The ex-dividend date of this dividend is Tuesday, November 21st. This represents a $0.22 annualized dividend and a yield of 0.69%. LeMaitre Vascular’s dividend payout ratio (DPR) is presently 28.57%.

About LeMaitre Vascular

LeMaitre Vascular, Inc is a provider of medical devices for the treatment of peripheral vascular disease. The Company develops, manufactures and markets medical devices and implants used primarily in the field of vascular surgery. It is engaged in the design, marketing, sales and technical support of medical devices and implants for the treatment of peripheral vascular disease industry segment.

Earnings History and Estimates for LeMaitre Vascular (NASDAQ:LMAT)

Receive News & Ratings for LeMaitre Vascular Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.